Peptide nasal sprays vs injections: which is better?

For decades, subcutaneous injection was the only serious option for peptide administration in research. Reconstitute with bacteriostatic water, draw with an insulin syringe, inject subcutaneously, refrigerate the remainder. It worked, but it introduced friction at every step — sterile technique, reconstitution math, needle disposal, cold storage of reconstituted solutions.

The rise of peptide nasal sprays over the past five years has fundamentally changed this calculation. Ready-to-use nasal formulations eliminate reconstitution entirely, require no needles, and deliver consistent metered doses through a pharmaceutical-grade atomizer. But are they as effective?

The honest answer: it depends on the peptide, the target tissue, and the research objective. This article breaks down the tradeoffs so you can make an informed decision for your specific protocol.

No reconstitution required

Injectable peptides ship as lyophilized powder. Before use, you need bacteriostatic water, sterile technique, and the math to calculate concentration per unit volume. With peptide nasal sprays, the peptide arrives in solution, pre-loaded in a metered-dose atomizer. Point, spray, done.

No needles, no sharps disposal

Needle-free delivery eliminates injection site reactions, bruising, and the need for proper sharps disposal. For protocols requiring frequent dosing, the cumulative convenience advantage of nasal delivery is substantial.

Bypass first-pass metabolism

Like subcutaneous injection, intranasal delivery bypasses first-pass hepatic metabolism. The peptide reaches systemic circulation without being broken down by liver enzymes — a significant advantage over oral administration, where most unprotected peptides are destroyed before reaching the bloodstream.

Potential CNS access

This is the unique advantage of intranasal delivery that no other route offers. The olfactory and trigeminal nerve pathways provide a direct transport route from the nasal cavity to the brain, partially bypassing the blood-brain barrier. We cover this in detail in the CNS section below.

Rapid absorption

The nasal epithelium is highly vascularized with a large surface area (approximately 150 cm² in humans). Small peptides are absorbed rapidly — onset of detectable plasma levels typically occurs within 10-15 minutes of intranasal administration, which is comparable to or faster than subcutaneous injection for many peptides.

Higher and more predictable bioavailability

Subcutaneous injection delivers essentially 100% of the peptide to the body. There is no mucociliary clearance, no variable absorption depending on nasal congestion, and no loss to the back of the throat. For dose-response studies where precise systemic exposure is critical, injection remains the gold standard.

Established PK profiles

The pharmacokinetics of most research peptides have been characterized via subcutaneous or intraperitoneal injection. Published dose-response curves, half-life measurements, and tissue distribution data are predominantly based on injection routes. When replicating published protocols, injection provides the most direct comparison to existing literature.

Works for larger peptides

Nasal absorption decreases with increasing molecular weight. Peptides above 30-40 amino acids or approximately 4,000 Da have progressively poor nasal bioavailability without permeation enhancers. Injection does not have this limitation — even large proteins can be delivered subcutaneously with high bioavailability.

Lower per-dose cost for some peptides

Lyophilized peptide vials are often less expensive per milligram than pre-formulated nasal sprays, because the spray requires pharmaceutical-grade atomizer hardware, aqueous formulation, and preservative optimization. For budget-sensitive research, the injectable format may stretch further.

Bioavailability — the fraction of administered peptide that reaches systemic circulation — is the most-discussed metric when comparing delivery routes. Here is how the routes stack up:

The 20-50% figure for peptide nasal sprays is a general range from the intranasal peptide delivery literature. The actual bioavailability for a specific peptide depends on molecular weight, charge, lipophilicity, the formulation vehicle, and whether permeation enhancers are used.

The most compelling scientific argument for peptide nasal sprays has nothing to do with convenience — it is about anatomy. The nasal cavity is the only external body surface with direct neural connections to the brain.

Two nerve pathways connect the nasal epithelium to the central nervous system:

• Olfactory nerve pathway — Olfactory receptor neurons project from the upper nasal cavity through the cribriform plate directly into the olfactory bulb and from there to the hippocampus, amygdala, and cortex. Compounds deposited on the olfactory epithelium can be transported along these neurons into the brain within minutes.
• Trigeminal nerve pathway — Branches of the trigeminal nerve innervate the respiratory epithelium throughout the nasal cavity and provide a second transport route to the brainstem and other CNS regions.

This nose-to-brain transport partially bypasses the blood-brain barrier — a structure that blocks most peptides from reaching the CNS when administered systemically. For neuropeptides like Semax, Selank, and Oxytocin, this direct CNS access is a primary reason the intranasal route is studied. It is also why intranasal Oxytocin has become the dominant delivery method in social cognition research, despite lower systemic bioavailability than injection.

For peptides targeting peripheral tissues (e.g., BPC-157 for tendon repair, TB-500 for systemic tissue recovery), the CNS access argument is less central — but the convenience and first-pass bypass advantages still apply.

Not every peptide is suitable for intranasal delivery. The ideal characteristics for nasal spray peptides are:

• Small molecular weight — Under approximately 4,000 Da (roughly 30 amino acids). Smaller peptides cross the nasal epithelium more readily.
• Aqueous stability — The peptide must remain stable in solution for weeks to months at refrigerator temperatures.
• Relevant CNS or systemic targets — The nasal route makes sense when the target is either in the CNS (where nose-to-brain transport is an advantage) or systemically accessible via the highly vascular nasal mucosa.

The peptides in our catalog that are particularly well-suited for nasal delivery include:

• BPC-157 — 15 amino acids, 1,419 Da. Exceptionally stable. Studied for tissue repair and neuroprotection via both peripheral and CNS pathways.
• Semax — 7 amino acids, 814 Da. Originally designed for intranasal delivery. The research and clinical (Russian) evidence base is predominantly nasal.
• Selank — 7 amino acids, 752 Da. Same design lineage as Semax — engineered for nasal delivery from inception.
• Oxytocin — 9 amino acids, 1,007 Da. The most-studied intranasal peptide globally, with hundreds of published trials using nasal delivery.
• PT-141 — 7 amino acids, 1,025 Da. Acts centrally via melanocortin receptors — nasal delivery aligns with the CNS target.
• DSIP — 9 amino acids, 849 Da. Targets sleep architecture through central mechanisms — intranasal is the natural fit.

The decision between peptide nasal sprays and injections comes down to four factors:

1. Your research target

If your research involves CNS endpoints — cognition, behavior, neuroprotection, sleep architecture — intranasal delivery provides unique nose-to-brain access that injection cannot match. If your focus is purely peripheral (muscle, tendon, gut), injection gives higher systemic bioavailability.

2. Protocol frequency

For protocols requiring daily or twice-daily dosing, the convenience of nasal spray administration significantly reduces protocol friction. For single-dose or weekly protocols, injection complexity is manageable.

3. Dose precision requirements

If your protocol requires precise, reproducible systemic exposure, subcutaneous injection with calibrated syringes is superior. Nasal sprays deliver consistent metered doses per actuation, but total absorbed dose has higher variability due to mucociliary clearance and individual nasal anatomy.

4. Existing literature basis

If you are replicating a published protocol, use the same route as the original study. For Semax and Selank, that is intranasal. For many BPC-157 studies, that is intraperitoneal. Choose the route that makes your results comparable to the existing evidence base.